Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Booster programme welcome but plans must be in place for boosters for all vaccinated people

09/20/2021 | 10:17am EDT

Health Secretary Sajid Javid has confirmed that a programme of COVID-19 booster vaccinations will begin this week for people 50 and over and those with underlying health conditions. The Harley Street Health Centre has been conducting an ongoing audit on antibody levels in vaccinated people since the vaccination programme began, testing antibody levels over time in the same individuals, using the Roche quantitative antibody test. The audit supports other research on waning vaccine efficacy over time, with steady antibody reduction seen in all participants

The post Booster programme welcome but plans must be in place for boosters for all vaccinated people appeared first on PR Fire.

Health Secretary Sajid Javid has confirmed that a programme of COVID-19 booster vaccinations will begin this week for people 50 and over and those with underlying health conditions.

The Harley Street Health Centre has been conducting an ongoing audit on antibody levels in vaccinated people since the vaccination programme began, testing antibody levels over time in the same individuals, using the Roche quantitative antibody test.

The audit supports other research on waning vaccine efficacy over time, with steady antibody reduction seen in all participants. For some participants who had their first vaccine in the earliest groups, antibodies are no longer detectable.

Clinical director Dr Enam Abood commented,

"Although antibody levels do not tell the whole immunity story, we are concerned that a booster programme for only select groups returns many adults in the UK to a previous vulnerable position, where their ability to fight this virus deteriorates significantly after 6 months to a year. We strongly encourage the government to roll out a nationwide vaccination booster programme, for all vaccinated adults. There is a risk that we undo all of the incredible work achieved over this year and stop impacting transmission and mutations by not being definitive in this action."

She continued,

"Understandably, in the midst of a pandemic, our focus is entirely on preventing hospitalisations and death. But there are a growing number of adults and young people in the UK developing longer term symptoms, that can be life-changing and debilitating, and we cannot allow this to become our norm. We are looking at a future health crisis."

www.harleyhealthcentre.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about ROCHE HOLDING AG
06:52aROCHE HOLDINGS AG : Deutsche Bank reiterates its Buy rating
MD
10/25CHUGAI PHARMACEUTICAL : Notice of Revisions to Financial Forecasts
AQ
10/25CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
AQ
10/25CHUGAI PHARMACEUTICAL : Construction of New Bio API Plant for Early Clinical Trials to Acc..
AQ
10/25CHUGAI PHARMACEUTICAL : Notice of Revisions to Dividend Forecast for Fiscal Year Ending De..
AQ
10/25CHUGAI PHARMACEUTICAL : announced Organizational Changes
AQ
10/25ROCHE : Launches Genomic Profiling Kit To Aid Cancer Research
MT
10/25ROCHE : launches comprehensive genomic profiling kit to expand access to personalised canc..
AQ
10/25PRESS RELEASE : Roche launches comprehensive genomic profiling kit to expand access to per..
DJ
10/24ROCHE : Secures US FDA Approval For Neovascular Age-Related Macular Degeneration Treatment
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 031 M 67 449 M 67 449 M
Net income 2021 15 034 M 16 347 M 16 347 M
Net cash 2021 4 732 M 5 146 M 5 146 M
P/E ratio 2021 20,0x
Yield 2021 2,62%
Capitalization 311 B 338 B 339 B
EV / Sales 2021 4,94x
EV / Sales 2022 4,80x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 357,95 CHF
Average target price 383,75 CHF
Spread / Average Target 7,21%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG15.61%338 364
JOHNSON & JOHNSON5.32%431 938
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.22%241 929
ELI LILLY AND COMPANY47.15%222 158
MERCK & CO., INC.-0.17%206 712